Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
CERE was delisted on the 31st of July, 2024.
231 hedge funds and large institutions have $6.42B invested in Cerevel Therapeutics Holdings, Inc. Common Stock in 2024 Q2 according to their latest regulatory filings, with 43 funds opening new positions, 82 increasing their positions, 69 reducing their positions, and 20 closing their positions.
115% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 20
60% more funds holding in top 10
Funds holding in top 10: 10 → 16 (+6)
19% more repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 69
10% more funds holding
Funds holding: 210 → 231 (+21)
4% less capital invested
Capital invested by funds: $6.67B → $6.42B (-$254M)
12% less call options, than puts
Call options by funds: $149M | Put options by funds: $169M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Norges Bank
Oslo,
Norway
|
+$67.1M |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$44.1M |
| 3 |
SGCM
Sand Grove Capital Management
London,
United Kingdom
|
+$38.3M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$36.3M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$32.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$78.6M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$74.4M |
| 3 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$51.2M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
-$38.2M |
| 5 |
Man Group
London,
United Kingdom
|
-$26.7M |
CERE Hedge Fund Activity: Q2 2024 in Review
231 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) for Q2 2024, worth a combined $6.42B — down 3.8% from $6.67B a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new CERE positions and 20 closed out — a net gain of 23 holders — while 82 added to existing stakes and 69 trimmed.
The largest buyer was Norges Bank, adding an estimated $67.1M. The largest seller was BlackRock, cutting an estimated $78.6M.
- 231 institutional investors held Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) as of Q2 2024, up from 210 in Q1 2024.
- Funds reported $6.42B of Cerevel Therapeutics Holdings, Inc. Common Stock stock for Q2 2024, down 3.8% quarter-over-quarter.
- 43 funds opened new Cerevel Therapeutics Holdings, Inc. Common Stock positions in Q2 2024 and 20 closed out, a net change of +23 holders.
- The largest Cerevel Therapeutics Holdings, Inc. Common Stock buyer in Q2 2024 was Norges Bank, an estimated $67.1M added.
- The largest Cerevel Therapeutics Holdings, Inc. Common Stock seller in Q2 2024 was BlackRock, an estimated $78.6M sold.
Based on aggregated 13F filings for Q2 2024.